Albany, NY -- (SBWIRE) -- 07/26/2019 -- Diabetic Foot Ulcers Market Insights, Epidemiology, and Market Forecast- 2028
1. The global diabetic foot ulcer prevalence was 6.3%, which was higher in males than in females.
2. North America had the highest Diabetic Foot Ulcers prevalence, Oceania had the lowest and Diabetic Foot Ulcers prevalence in Europe, and Africa were 5.1% and 7.2%, respectively.
3. 10-30% of diabetic patients with a foot ulcer will eventually progress to amputation. The prevalence of foot ulcers among diabetic patients ranges from 2% to 12%.
DelveInsight launched a new report on Diabetic Foot Ulcers Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Diabetic Foot Ulcers market report covers a descriptive overview and comprehensive insight of the Diabetic Foot Ulcers epidemiology and Diabetic Foot Ulcers market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Diabetic Foot Ulcers market report provides insights on the current and emerging therapies.
3. Diabetic Foot Ulcers market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Diabetic Foot Ulcers market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Diabetic Foot Ulcers market.
Request for sample pages
"Over 55 million Europeans suffer from diabetes, and 8 million of these patients are at risk of developing a diabetic foot ulcer."
The primary goal in Diabetic Foot Ulcers treatment is to obtain wound closure. Management of the foot ulcer is largely determined by its severity (grade) and vascularity, and the presence of infection.
Diabetic Foot Ulcers Treatment of the underlying ischemia is critical in achieving a successful outcome, regardless of topical therapies. Vascular surgical consultation can be obtained when a patient presents with an ischemic wound and when ulcers show no sign of progress despite appropriate management. A major component of the limb salvage strategy in these patients is extreme distal arterial reconstruction to restore pulsatile flow to the foot. The role of isolated distal endovascular procedures in this setting has not been determined. Vasodilator drugs have not been beneficial in promoting healing of ischemic lesions. Whereas hyperbaric oxygen therapy has been used as adjunctive treatment of foot ulcers; however, support for its use is limited by the small number of carefully controlled clinical trials.
When the infection is present, aerobic and anaerobic cultures can be obtained, followed by the initiation of appropriate broad-spectrum antibiotic therapy. Antibiotic coverage can subsequently be tailored according to the clinical response of the patient, culture results, and sensitivity testing. Surgical drainage, deep debridement, or local partial foot amputations are necessary adjuncts to antibiotic therapy of infections that are deep or limb-threatening. Underlying osteomyelitis is frequently present in patients with moderate-to-severe infections and requires aggressive bony resection of infected bone and joints followed by four to six weeks of culture-directed antibiotic therapy. The presence of deep infection with abscess, cellulitis, gangrene, or osteomyelitis is an indication for hospitalization and prompts surgical drainage. Even in the absence of bone infection, foot-sparing reconstructive procedures might be necessary to achieve final healing of the foot ulcer, especially in areas subject to exceedingly high plantar or shoe pressures.
The launch of the emerging therapies is expected to significantly impact the Diabetic Foot Ulcers treatment scenario in the upcoming years:-
Drugs covered
1. Plasma-generated nitric oxide
2. MBN-101
3. DermaPro (CL05)
And many others
The key players in Diabetic Foot Ulcers market are:
1. Originww
2. Microbion Corporation
3. CytoTools AG
And many others
Table of contents
1. Report Introduction
2. Diabetic Foot Ulcers Market Overview at a Glance
3. Diabetic Foot Ulcers Disease Background and Overview
4. Diabetic Foot Ulcers Epidemiology and Patient Population
5. Diabetic Foot Ulcers Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Diabetic Foot Ulcers Treatment & Medical Practices
7. Diabetic Foot Ulcers Marketed Drugs
7.1. Regranex Gel (becaplermin): Smith & Nephew
8. Diabetic Foot Ulcers Emerging Therapies
8.1. Key Cross Competition
8.2. Plasma-generated nitric oxide: Originww
8.3. MBN-101: Microbion Corporation
9. Diabetic Foot Ulcers Market Size
10. 7MM Diabetic Foot Ulcers Country-Wise Market Analysis
10.1. United States
10.2. Germany
10.3. France
10.4. Italy
10.5. Spain
10.6. United Kingdom
10.7. Japan
11. Diabetic Foot Ulcers Report Methodology
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight